Nektar Therapeutics
Nektar Therapeutics, a leading biopharmaceutical company headquartered in the United States, focuses on innovative drug development to address unmet medical needs. Founded in 1990, Nektar has made significant strides in the industry, particularly in the fields of oncology, immunology, and pain management. The company is renowned for its proprietary drug delivery technologies, which enhance the efficacy and safety of therapeutic agents. Nektar's core products, including its advanced therapies for cancer and chronic pain, stand out due to their unique mechanisms of action and patient-centric design. With a strong market position, Nektar Therapeutics has achieved notable milestones, including strategic partnerships and a robust pipeline of clinical candidates, solidifying its reputation as a pioneer in the biopharmaceutical landscape.
DitchCarbon Score
How does Nektar Therapeutics's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Chemicals industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Nektar Therapeutics's score of 13 is higher than 59% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Nektar Therapeutics's reported carbon emissions
Nektar Therapeutics, headquartered in the US, currently does not have publicly available carbon emissions data or specific reduction targets. Without emissions figures, it is challenging to assess their carbon footprint or the scope of their emissions (Scope 1, 2, or 3). Additionally, there are no documented climate commitments or initiatives aimed at reducing their environmental impact. As the industry increasingly prioritises sustainability, Nektar Therapeutics may need to establish clear climate goals and reporting practices to align with global standards and stakeholder expectations.
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Nektar Therapeutics is not committed to any reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
